Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2025 Oct 9;146(15):1862-1867.
doi: 10.1182/blood.2025029556.

Induction chemotherapy and molecular MRD influence outcomes in KMT2A-rearranged AML

Jad Othman  1   2   3 , Nicola Potter  1 , Sylvie D Freeman  4 , Nicholas McCarthy  4 , Jelena Jovanovic  1 , Manohursingh Runglall  1   5 , Joanna Canham  6 , Ian Thomas  6 , Sean Johnson  6 , Amanda Gilkes  7 , Jamie Cavenagh  8 , Panagiotis Kottaridis  9 , David Taussig  10 , Claire Arnold  11 , Claire Hemmaway  12 , Dominic Culligan  13 , Ulrik Malthe Overgaard  14 , Mike Dennis  15 , Alan K Burnett  16 , Nigel H Russell  2 , Richard Dillon  1   2
Affiliations
Randomized Controlled Trial

Induction chemotherapy and molecular MRD influence outcomes in KMT2A-rearranged AML

Jad Othman et al. Blood. .

Abstract

We analyzed 217 patients with KMT2A-rearranged acute myeloid leukemia (AML) in 2 large sequential randomized trials. Those randomized to FLAG-Ida (fludarabine, cytarabine, granulocyte colony-stimulating factor, idarubucin) had markedly lower rates of relapse than other chemotherapy regimens. Molecular measurable residual disease assessment after cycle 2 was strongly prognostic for relapse and death. The trials were registered at the ISRCTN Registry as AML17 ISRCTN55675535 and AML19 ISRCTN78449203.

PubMed Disclaimer

Publication types

MeSH terms